This study shows faecal transplant therapy improves symptoms in non-alcoholic fatty liver disease, indicating a greater benefit for lean patients.
Non-alcoholic fatty liver disease (NAFLD) is caused due to the tendency of the liver to build up fat in the liver causes Steatohepatitis. Unfortunately, in the present scenario, no specific treatment modality is available for a complete cure. The only way to manage this by lifestyle changes such as healthy diet, exercise, and weight management, but often difficult to guarantee for cure as well. Several human studies have legitimate evidence for the differences in the gut microbial population in patients with non-alcoholic steatohepatitis or non-alcoholic fatty liver disease. It is interesting to observe that even the characteristics of the gut microbiota between lean and obese patients varied in a wide range, and the patients in the two groups showed different responses to faecal transplant treatment. Faecal transplant therapy (FMT) could improve both lean and obese patients, but the treatment effect on lean patients was more promising than on obese patients. Taking advantage of FMT to prebiotic with beneficial bacteria could be a future challenge and success in therapeutics to cure non-alcoholic fatty liver disease.
No takes yet. Share an insight, caveat, or question.
P D Gupta (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: